CERT Stock Overview
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CERT passed our risk checks.
Certara, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.08 |
| 52 Week High | US$24.96 |
| 52 Week Low | US$10.60 |
| Beta | 1.46 |
| 1 Month Change | -11.39% |
| 3 Month Change | -19.59% |
| 1 Year Change | 8.98% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -63.03% |
Recent News & Updates
Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)?
Sep 17
An Intrinsic Calculation For Certara, Inc. (NASDAQ:CERT) Suggests It's 29% Undervalued
Aug 30Recent updates
Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)?
Sep 17An Intrinsic Calculation For Certara, Inc. (NASDAQ:CERT) Suggests It's 29% Undervalued
Aug 30Certara (NASDAQ:CERT) Shareholders Will Want The ROCE Trajectory To Continue
Aug 03Certara: A Story To Watch
Sep 27Certara to raise capital in secondary stock offering
Aug 12Certara Looks Positioned For Increased Growth In 2022
Feb 02Certara: Global Biosimulation Firm Positions Itself For Stability Into The Long Term
Sep 29Certara, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Certara, Inc. (NASDAQ:CERT) Is About To Turn The Corner
Apr 15How Much Of Certara, Inc. (NASDAQ:CERT) Do Insiders Own?
Mar 11Certara lands bull rating from BofA after quiet period ends
Jan 05Shareholder Returns
| CERT | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -0.1% | -3.2% | -3.1% |
| 1Y | 9.0% | 0.7% | 15.1% |
Return vs Industry: CERT exceeded the US Healthcare Services industry which returned 1.1% over the past year.
Return vs Market: CERT underperformed the US Market which returned 15.3% over the past year.
Price Volatility
| CERT volatility | |
|---|---|
| CERT Average Weekly Movement | 5.5% |
| Healthcare Services Industry Average Movement | 9.7% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in US Market | 14.2% |
| 10% least volatile stocks in US Market | 2.5% |
Stable Share Price: CERT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: CERT's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,177 | Bill Feehery | https://www.certara.com |
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers’ new drugs through the regulatory submission process and into the market.
Certara, Inc. Fundamentals Summary
| CERT fundamental statistics | |
|---|---|
| Market Cap | US$2.25b |
| Earnings (TTM) | US$19.17m |
| Revenue (TTM) | US$352.08m |
117.3x
P/E Ratio6.4x
P/S RatioIs CERT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CERT income statement (TTM) | |
|---|---|
| Revenue | US$352.08m |
| Cost of Revenue | US$135.67m |
| Gross Profit | US$216.41m |
| Other Expenses | US$197.24m |
| Earnings | US$19.17m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 61.47% |
| Net Profit Margin | 5.45% |
| Debt/Equity Ratio | 26.6% |
How did CERT perform over the long term?
See historical performance and comparison